ADMA Biologics Inc ( (ADMA) ) has released its Q3 earnings. Here is a breakdown of the information ADMA Biologics Inc presented to its investors.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ADMA Biologics, Inc. is a biopharmaceutical company that specializes in the manufacture and development of specialty biologics for treating immunodeficient patients and preventing infectious diseases. In its third-quarter earnings report for 2024, ADMA Biologics announced a substantial increase in both revenue and net income, with total revenue reaching $119.8 million, marking a 78% increase year-over-year. The company’s GAAP net income saw a dramatic rise of 1,300% to $35.9 million, while Adjusted EBITDA increased by 256% to $45.4 million.
Key highlights from ADMA Biologics’ latest financial results include a notable improvement in corporate gross margins, which increased from 37% to 50% year-over-year. The growth was driven largely by increased sales of the company’s immunoglobulin products, particularly ASCENIV, which now accounts for over 50% of total revenue. ADMA’s strategic initiatives, such as enhancing production yields and expanding its high-margin product portfolio, are expected to further bolster margins and earnings.
Additionally, ADMA Biologics announced its inclusion in the S&P SmallCap 600 Index, which is anticipated to enhance the company’s visibility within the investment community. The company has also engaged KPMG LLP as its new independent auditor, a move signifying ADMA’s improved financial standing. The expansion of ADMAlytics, an AI and machine learning platform, is expected to optimize commercial growth strategies, contributing to earnings growth.
Looking ahead, ADMA Biologics has revised its financial guidance for 2024 and 2025 upwards, with total revenue expected to exceed $415 million and $465 million, respectively. The company is optimistic about its growth prospects, with plans to achieve a net leverage-neutral position by the end of the year and continue strengthening its balance sheet, paving the way for sustained growth into 2025 and beyond.
